Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 201–300 of 1,000
Li, Z., Han, P., You, Z., Li, X., Zhang, Y., Yu, H., Nie, R., & Chen, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-10724-0 · Cited by 111
“Based on the equations (9), (10) and (11), the minimization of the equation (8) can be represented as”
BackgroundComputational systems biology in disease modeling and control, review and perspectives
Yue, R., & Dutta, A. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00247-4 · Cited by 120
Yang, L., Chen, J., & He, L. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000441 · Cited by 99
“The basic hypothesis of the CPI The hypothesis that drugs with similar phenotypic effects tend to interact with same targets is similar to a recent study done by Campillos et al [40].”
ResultInfluentialNetwork-Based Approaches in Drug Discovery and Early Development
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.176 · Cited by 96
“36,37”
Janga, S. C., & Tzakos, A. G. (2009) · Molecular BioSystems · doi:10.1039/b908147j · Cited by 110
Hoehndorf, R., Schofield, P. N., & Gkoutos, G. V. (2015) · Scientific Reports · doi:10.1038/srep10888 · Cited by 100
“…has major applications for biomedical research, and several studies have primarily relied on disease phenotypes to reveal functional disease modules 12,26,35 , candidate genes of disease 14,37 , prioritize genes in GWAS studies 38 , and investigate drug targets and indications 17,18,39,40 .”
BackgroundNetwork Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity
Brouwers, L., Iskar, M., Zeller, G., van Noort, V., & Bork, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022187 · Cited by 104
“However many of these similarities are expected to arise because drugs have one or more drug targets in common [4].”
BackgroundMethodSelf-citationTherapeutic implications of tumor interstitial acidification
Kolosenko, I., Avnet, S., Baldini, N., Viklund, J., & Milito, A. D. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.008 · Cited by 109
Cao, D., Zhang, L., Tan, G., Xiang, Z., Zeng, W., Xu, Q., & Chen, A. F. (2014) · Molecular Informatics · doi:10.1002/minf.201400009 · Cited by 102
Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method
Cheng, F., Zhou, Y., Li, W., Liu, G., & Tang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041064 · Cited by 100
Cheng, F., Li, W., Wu, Z., Wang, X., Zhang, C., Li, J., Liu, G., & Tang, Y. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400010x · Cited by 113
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs
Binda, C., Aldeco, M., Geldenhuys, W. J., Tortorici, M., Mattevi, A., & Edmondson, D. E. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200196p · Cited by 100
Network Pharmacology: Exploring the Resources and Methodologies
Junaid, M., Khan, A., Ali, A., Fang, L., Yanjing, W., Xu, Q., & Wei, D. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180330141351 · Cited by 105
Understanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 108
“Finally, by using in vitro biochemical assays, they confirmed common target binding (Campillos et al., 2008).”
Lessons learnt from the DDIExtraction-2013 Shared Task
Segura-Bédmar, I., Martínez, P., & Herrero-Zazo, M. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.05.007 · Cited by 108
DASPfind: new efficient method to predict drug–target interactions
Ba-alawi, W., Soufan, O., Essack, M., Kalnis, P., & Bajic, V. B. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0128-4 · Cited by 99
“In future, we plan to add different types of information, like drug side effects [26] and information derived from integrating multiple biological databases [27].”
BackgroundTargeting acidity in cancer and diabetes
Gillies, R. J., Pilot, C., Marunaka, Y., & Fais, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.003 · Cited by 108
Jin, G., Fu, C., Zhao, H., Cui, K., Chang, J. C., & Wong, S. T. C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2333 · Cited by 104
“The study of drug repositioning has so far been limited to the "on-target repositioning" that applies a drug's known pharmacologic mechanism to a different therapeutic indication, for example, comparing the structural similarities of small molecules (1, 2) or known side effects (3).”
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Kingsmore, K. M., Grammer, A. C., & Lipsky, P. E. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0337-0 · Cited by 100
A new method for computational drug repositioning using drug pairwise similarity
Li, J., & Lu, Z. (2012) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2012.6392722 · Cited by 103
The Chemical Basis of Pharmacology
Keiser, M. J., Irwin, J. J., & Shoichet, B. K. (2010) · Biochemistry · doi:10.1021/bi101540g · Cited by 94
“screens (58), and predicted off-targets and new disease indications for drugs (40).”
BackgroundTurning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Drug-target interaction prediction: A Bayesian ranking approach
Peška, L., Búza, K., & Koller, J. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.09.003 · Cited by 95
“, [9,19–21]), drugs’ side-effects [22], and the knowledge of already confirmed DTIs [23–32].”
BackgroundRevealing Drug-Target Interactions with Computational Models and Algorithms
Zhou, L., Li, Z., Yang, J., Tian, G., Liu, F., Wen, H., Li, P., Chen, M., Xiang, J., & Peng, L. (2019) · Molecules · doi:10.3390/molecules24091714 · Cited by 101
“[47] exploited a drug side-effect similarity-based inference method (DSSI).”
MethodParsing interindividual drug variability: an emerging role for systems pharmacology
Turner, R. M., Park, B. K., & Pirmohamed, M. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1302 · Cited by 90
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures
Lee, H., Kang, S., & Kim, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150460 · Cited by 90
Park, K., Kim, D., Ha, S., & Lee, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140816 · Cited by 102
Recent Advances of Utilizing Artificial Intelligence in Lab on a Chip for Diagnosis and Treatment
Zare Harofte, S., Soltani, M., Siavashy, S., & Raahemifar, K. (2022) · Small · doi:10.1002/smll.202203169 · Cited by 91
Drug–drug interaction prediction: databases, web servers and computational models
Zhao, Y. F., Yin, J., Zhang, L., Zhang, Y., & Chen, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad445 · Cited by 110
“In addition, following the previous research [55], the drug phenotypic similarity score P-score ij between d i and d j was calculated based on the clinical side effects of drugs.”
MethodSystems pharmacology and genome medicine: a future perspective
Wist, A. D., Berger, S., & Iyengar, R. (2009) · Genome Medicine · doi:10.1186/gm11 · Cited by 95
“Recent work has generated a network connecting drugs on the basis of their structural similarity and similarity of side-effect profiles [43].”
BackgroundLee, H. S., Bae, T., Lee, J.-H., Kim, D. G., Oh, Y. S., Jang, Y., Kim, J.-T., Lee, J.-J., Innocenti, A., Supuran, C. T., et al. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-80 · Cited by 87
“For instance, drug repositioning approaches have incorporated in silico approaches for analyzing large data sets such as gene expression profiles [4,5], literature mining [6], chemical similarity [7], side-effect similarity [8], disease-drug network [9], pathway-based disease network [10], and phenotypic disease netwo…”
BackgroundComputational drug repositioning for rare diseases in the era of precision medicine
Delavan, B., Roberts, R., Huang, R., Bao, W., Tong, W., & Liu, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.009 · Cited by 85
Network-based analysis of complex diseases
Liu, Z.-P., Wang, Y., Zhang, X.-S., & Chen, L. (2012) · IET Systems Biology · doi:10.1049/iet-syb.2010.0052 · Cited by 91
A co-module approach for elucidating drug–disease associations and revealing their molecular basis
Zhao, S., & Li, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts057 · Cited by 89
Text Mining for Drugs and Chemical Compounds: Methods, Tools and Applications
Vazquez, M., Krallinger, M., Leitner, F., & Valencia, A. (2011) · Molecular Informatics · doi:10.1002/minf.201100005 · Cited by 87
Deep learning-based transcriptome data classification for drug-target interaction prediction
Xie, L., He, S., Song, X., Bo, X., & Zhang, Z. (2018) · BMC Genomics · doi:10.1186/s12864-018-5031-0 · Cited by 98
DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration
Wang, Y., Yang, Y., Chen, S., & Wang, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab048 · Cited by 94
Direct and Selective Electrocarboxylation of Styrene Oxides with CO2 for Accessing β‐Hydroxy Acids
Zhang, K., Ren, B., Liu, X., Wang, L., Zhang, M., Ren, W., Lu, X., & Zhang, W. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202207660 · Cited by 86
Wang, Y., Liu, Z., Li, C., Li, D., Ouyang, Y., Yu, J., Guo, S., He, F., & Wang, W. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/698531 · Cited by 94
Vogt, I., & Mestres, J. (2010) · Molecular Informatics · doi:10.1002/minf.200900069 · Cited by 94
Wang, X., Xu, X. J., Tao, W., Li, Y., Wang, Y., & Yang, L. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/519031 · Cited by 89
“Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 519031, 15 pages doi:10.1155/2012/519031 Research Article”
BackgroundInfluentialAdvanced Systems Biology Methods in Drug Discovery and Translational Biomedicine
Zou, J., Zheng, M.-W., Li, G., & Su, Z. (2013) · BioMed Research International · doi:10.1155/2013/742835 · Cited by 90
“Several unexpected drug-drug relations are formed by chemically dissimilar drugs from different therapeutic indications, which implies new drug-target relations [51].”
BackgroundChakraborty, C., Bhattacharya, M., Lee, S., Wen, Z., & Lo, Y.-H. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102295 · Cited by 99
Drug-target and disease networks: polypharmacology in the post-genomic era
Masoudi‐Nejad, A., Mousavian, Z., & Bozorgmehr, J. H. (2013) · In Silico Pharmacology · doi:10.1186/2193-9616-1-17 · Cited by 83
“To predict the drug-target interaction, another interesting approach was proposed by Campillos et al. based on the side-effect similarities between known drugs (Campillos et al. 2008).”
MethodBajorath, J. (2015) · F1000Research · doi:10.12688/f1000research.6653.1 · Cited by 80
Hong, D. S., Sebti, S. M., Newman, R. A., Blaskovich, M. A., Ye, L., Gagel, R. F., Moulder, S., Wheler, J. J., Naing, A., Tannir, N. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1241 · Cited by 82
Wang, F., Liu, D., Wang, H., Luo, C., Zheng, M., Liu, H., Zhu, W., Luo, X., Zhang, J., & Jiang, H. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200264h · Cited by 80
Qiu, C., Chen, G., & Cui, Q. (2012) · Scientific Reports · doi:10.1038/srep00318 · Cited by 84
“For example, the analysis and modeling of one class of important environmental factors, drugs, and their interactions with their targets (GFs) has revealed a number of important insights 2 and identified new drug-target interactions 3 .”
BackgroundDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders
Lee, H.-M., & Kim, Y. (2016) · Schizophrenia Research and Treatment · doi:10.1155/2016/6378137 · Cited by 80
Mahmud, S., Chen, W., Han, M., Jahan, H., Liu, Y., & Hasan, S. M. M. (2019) · Analytical Biochemistry · doi:10.1016/j.ab.2019.113507 · Cited by 85
Prediction of drug-target interactions based on multi-layer network representation learning
Shang, Y., Gao, L., Zou, Q., & Yu, L. (2020) · Neurocomputing · doi:10.1016/j.neucom.2020.12.068 · Cited by 85
Vitali, F., Cohen, L. D., Demartini, A., Amato, A. M., Eterno, V., Zambelli, A., & Bellazzi, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162407 · Cited by 90
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Wu, L., Ingle, T., Liu, Z., Zhao-Wong, A., Harris, S., Thakkar, S., Zhou, G., Yang, J., Xu, J., Mehta, D., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2628-5 · Cited by 80
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Bisgin, H., Liu, Z., Kelly, R., Fang, H., Xu, X., & Tong, W. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s15-s6 · Cited by 76
“[14] investigated off-target effects by integrating side effect profiles with chemical structures and identified several new drugtarget interactions.”
BackgroundUnderstanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 87
Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 84
Ligand-Based Approaches to In Silico Pharmacology
Vidal, D., García-Serna, R., & Mestres, J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_19 · Cited by 85
Extracting Sets of Chemical Substructures and Protein Domains Governing Drug-Target Interactions
Yamanishi, Y., Pauwels, E., Saigo, H., & Stoven, V. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100476q · Cited by 79
In silico prediction of chemical mechanism of action via an improved network‐based inference method
Wu, Z., Lü, W., Wu, D., Luo, A., Bian, H., Li, J., Li, W., Liu, G., Huang, J. Y., Cheng, F., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13629 · Cited by 85
“, 2012c), similarity-based (Campillos et al., 2008; Keiser et al., 2009; Cheng et al., 2013), network-based (Cheng et al.”
Drug repurposing for cancer therapy, easier said than done
González‐Fierro, A., & Dueñas‐González, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.012 · Cited by 85
Computational Tools for Polypharmacology and Repurposing
Achenbach, J., Tiikkainen, P., Franke, L., & Proschak, E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.62 · Cited by 77
DrugClust: A machine learning approach for drugs side effects prediction
Dimitri, G. M., & Lió, P. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.03.008 · Cited by 78
Bultum, L. E., Tolossa, G. B., Kim, G., Kwon, O., & Lee, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-26446-x · Cited by 88
Cheng, T., Li, Q., Wang, Y., & Bryant, S. H. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200192v · Cited by 85
The Recognition of Identical Ligands by Unrelated Proteins
Barelier, S., Sterling, T., O’Meara, M. J., & Shoichet, B. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00683 · Cited by 74
Jiang, W., Chen, X., Liao, M., Li, W., Lian, B., Wang, L., Meng, F., Liu, X., Chen, X., Jin, Y., et al. (2012) · Scientific Reports · doi:10.1038/srep00282 · Cited by 82
Zhang, P., Wang, F., & Hu, J. (2014) · PubMed Central · Cited by 94
Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine
Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 81
“include existing known drug targets and their homologs, which only cover a small portion (,8%) of the human genome [77–95].”
BackgroundLiu, Z., Guo, F., Gu, J., Wang, Y., Li, Y., Wang, D., Lu, L., Li, D., & He, F. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv055 · Cited by 79
Wang, K., Sun, J., Zhou, S., Wan, C., Qin, S., Li, C., He, L., & Yang, L. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003315 · Cited by 78
“For example, methods have been established to predict DTI by ligand/protein structures [11–16] and clinical side effects [17].”
MethodDeep learning in target prediction and drug repositioning: Recent advances and challenges
Yu, J., Dai, Q.-Q., & Li, G. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.010 · Cited by 82
Rational Polytherapy with Antiepileptic Drugs
Lee, J. W., & Dworetzky, B. A. (2010) · Pharmaceuticals · doi:10.3390/ph3082362 · Cited by 80
“Furthermore, even if two drugs with completely different mechanisms of antiepileptic action are selected, they may each be prone to similar side effects and in combination cause exaggerated additive/supra-additive side effects by acting upon common but unidentified targets unrelated to their antiepileptic mechanisms […”
BackgroundProceedings of the BioNLP 2018 workshop
(2018) · doi:10.18653/v1/w18-23 · Cited by 71
Systematic prediction of drug combinations based on clinical side-effects
Huang, H., Zhang, P., Qu, X. A., Sanseau, P., & Yang, L. (2014) · Scientific Reports · doi:10.1038/srep07160 · Cited by 73
“We hypothesize that the drugs that can be put together usually do nothaveoverlap insomeserious adversedrug reactions (ADR),but might share some SEs that contribute to the therapeutic effect 16,17 .”
BackgroundMuñoz, E., Nováček, V., & Vandenbussche, P.-Y. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbx099 · Cited by 76
“Most state-of-the-art techniques adopt a drug-centric approach and rely on the assumption that similar drugs share the same properties, mechanism of action and therefore also ADRs [15, 16].”
BackgroundMethodConnecting chemistry and biology through molecular descriptors
Fernández-Torras, A., Comajuncosa-Creus, A., Duran-Frigola, M., & Aloy, P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.09.001 · Cited by 68
Luo, H., Zhang, P., Huang, H., Huang, J., Kao, E., Shi, L. M., He, L., & Yang, L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku433 · Cited by 73
“Based on the independent validation data, we compared four prediction methods: (i) P-score that uses side-effect similarities to measure the connection between two drugs (39).”
MethodFacing the Challenges of Structure-Based Target Prediction by Inverse Virtual Screening
Schomburg, K. T., Bietz, S., Briem, H., Henzler, A. M., Urbaczek, S., & Rarey, M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500130e · Cited by 78
Network‐based drugs and biomarkers
Erler, J. T., & Linding, R. (2010) · The Journal of Pathology · doi:10.1002/path.2646 · Cited by 71
“Recent studies of the relationships between diseases have suggested that drug side-effects can be used to associate diseases [26] or that this can be done through analysis of changes to protein expression [15,27,28].”
BackgroundA Survey on the Computational Approaches to Identify Drug Targets in the Postgenomic Era
Dai, Y.-F., & Zhao, X.-M. (2015) · BioMed Research International · doi:10.1155/2015/239654 · Cited by 76
“Unfortunately, the Reference Data used Iskar et al. [14] Transcriptome profiles Reinhold et al. [18] Transcriptome profiles Cheng et al. [21] Transcriptome profiles Carrella et al. [49] Transcriptome profiles Xu et al. [50] Transcriptome profiles Zhao and Li [26] Molecular networks Li et al. [35] Molecular networks G¨…”
BackgroundArtificial Intelligence in Drug Treatment
Romm, E. L., & Tsigelny, I. F. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023746 · Cited by 80
SELF-BLM: Prediction of drug-target interactions via self-training SVM
Keum, J., & Nam, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171839 · Cited by 72
Drug side effect prediction through linear neighborhoods and multiple data source integration
Zhang, W., Chen, Y., Tu, S., Liu, F., & Qu, Q. (2016) · 2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2016.7822555 · Cited by 70
Iwata, H., Sawada, R., Mizutani, S., & Yamanishi, Y. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500670q · Cited by 81
Genomics and transcriptomics in drug discovery
Dopazo, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.003 · Cited by 73
A Pipeline for High-Throughput Concentration Response Modeling of Gene Expression for Toxicogenomics
House, J. S., Grimm, F. A., Jima, D. D., Zhou, Y.-H., Rusyn, I., & Wright, F. A. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00168 · Cited by 69
“, 2014) from either drug/chemical exposure or biological knockdown/knockout with 50 different cell types (Campillos et al., 2008) on a ∼1,000 gene-set with fulltranscriptome imputation.”
BackgroundMethodWild, D. J., Ding, Y., Sheth, A., Harland, L., Gifford, E., & Lajiness, M. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.019 · Cited by 68
Exploring the associations between drug side-effects and therapeutic indications
Wang, F., Zhang, P., Cao, N., Hu, J., & Sorrentino, R. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.03.014 · Cited by 74
“, side-effects [7,8] and connective map gene expression [9,10]).”
BackgroundLee, S., Lee, K. H., Song, M., & Lee, D. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s2-s2 · Cited by 70
“In their paper published in Science , Campellos et al reported finding new targets based on drugs with similar side effects [1].”
BackgroundBiochemical network-based drug-target prediction
Klipp, E., Wade, R. C., & Kummer, U. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.05.004 · Cited by 71
Zhou, W., Wang, J., Wu, Z., Huang, C., Lü, A., & Wang, Y. (2016) · Scientific Reports · doi:10.1038/srep36985 · Cited by 80
“Campillos et al. developed a computational algorithm for finding drug-target associations based on the information of drug side-effect similarity measure 21 .”
Lin, X., Zhao, K., Xiao, T. Y., Quan, Z., Wang, Z.-J., & Yu, P. S. (2020) · Frontiers in artificial intelligence and applications · doi:10.3233/faia200232 · Cited by 99
CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules
Lee, J. H., Kim, D. G., Bae, T., Rho, K., Kim, J. T., Lee, J.-J., Jang, Y., Kim, B. C., Park, K. M., & Kim, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042573 · Cited by 73
“Analyzing large data sets such as gene expression [15], chemical similarity [44], side-effect similarity [45], disease-drug network [46], and phenotypic disease network [47] has been applied for drug repositioning.”
BackgroundNetwork based elucidation of drug response: from modulators to targets
Iorio, F., Saez-Rodriguez, J., & Bernardo, D. D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-139 · Cited by 64
“Campillos et al [52] mined the Unified Medical Language System (UMLS) [53] ontology for medical symptoms and extracted informations about known side-effects of a large number of marketed drugs.”
BackgroundOptimal Drug Prediction From Personal Genomics Profiles
Sheng, J., Li, F., & Wong, S. T. C. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2412522 · Cited by 70
“Many approaches have been developed to reposition or repurpose known drugs to new indications [16], [17], based on the assumption that drugs sharing similar chemical structures would”
Chartier, M., Morency, L.-P., Zylber, M. I., & Najmanovich, R. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0128-7 · Cited by 71
“Drug off-targets were identified in a number of different ways using other binding-site similarity methods based for example on the detection of C-alpha similarities [28], side effect similarity [64] or data mined from social networks [65].”
MethodIslam, T., Rahman, M. R., Aydın, B., Beklen, H., Arğa, K. Y., & Shahjaman, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173594 · Cited by 70
“We used the Library of Integrated Network-based Cellular Signatures (LINCS) – L1000 data which covers gene expression data from ~50 human cell lines in response to ~20,000 compounds (Campillos et al., 2008).”
MethodLabute, M. X., Zhang, X., Lenderman, J., Bennion, B. J., Wong, S., & Lightstone, F. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106298 · Cited by 72
“[10] indicated that drugs with similar side effects have a correspondingly similar profile of protein targets.”
BackgroundRepurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records
Paik, H., Chung, A.-Y., Park, H.-C., Park, R. W., Suk, K., Kim, J., Kim, H., Lee, K., & Butte, A. J. (2015) · Scientific Reports · doi:10.1038/srep08580 · Cited by 59
“In equation (5), the higher score is mainly derived by the larger Pc, and minimum difference between Pg and Pc (Pc – Pg).”
Background
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.